Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2006-05-02 Earnings Release
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 2, 2006, reporting preliminary financial results for the quarter ended March 31, 2006. It references a press release (Exhibit 99.1) containing the financial results. The text does not contain detailed financial statements or substantive financial data itself but rather announces the results and includes a press release. The document length is 2641 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The presence of a press release announcing preliminary results aligns with the ER category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K). Therefore, the appropriate classification is Earnings Release (ER).
2006-05-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (lease amendment), other events (clinical trial initiation), and a press release attached as an exhibit. There are no financial statements or detailed financial data presented, only announcements of events and a press release. The document length is 3934 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories like Annual Report or Earnings Release.
2006-04-28 English
AUTO-GENERATED PAPER DOCUMENT
Annual Report
2006-04-20 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2006-03-29 English
PRELIMINARY PROXY STATEMENT
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Preliminary Proxy Statement (Schedule 14A) filed with the SEC for Targeted Genetics Corporation's 2006 Annual Meeting of Shareholders. It includes detailed information about the meeting agenda such as election of directors, approval of amendments to Articles of Incorporation including a reverse stock split, ratification of the independent auditor, and other shareholder voting matters. The document is clearly a solicitation of proxies and contains detailed proxy materials for shareholders to vote on corporate governance and other matters at the annual meeting. It is not an annual report, earnings release, or other financial report, but rather a proxy solicitation document. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2006-03-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the filing announces FDA approval to amend a clinical trial protocol and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2765 characters) and primarily serves as an announcement of an event rather than a detailed report. Therefore, it does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2006-03-16 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.